Share this video  

SABCS 2022 | Differential long-term benefit of adjuvant tamoxifen in ER+/HER2- premenopausal + postmenopausal BC

Annelie Johansson, PhD, Karolinska Institutet, Stockholm, Sweden, discusses differential long-term benefit from adjuvant tamoxifen therapy in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative premenopausal and postmenopausal breast cancer patients. Secondary analysis was carried out of 1242 ER-positive/HER2-negative patients from the Stockholm tamoxifen (STO)-trials who had been randomized to receive tamoxifen or no endocrine therapy with complete 20-years follow-up. When evaluating clinically used tumor characteristics, postmenopausal patients with a low-risk were observed to obtain a long-term benefit from tamoxifen, whereas fewer clinically used tumor characteristics corresponding to good prognosis were associated with tamoxifen benefit in premenopausal patients. Time-varying analysis in premenopausal patients indicated that tamoxifen therapy benefit diminished over time, whereas postmenopausal patients were shown to have longer-term benefit. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.